MUMBAI, India, Oct. 5 -- Intellectual Property India has published a patent application (202621099832 A) filed by Mehta Drashti Anilkumar; and Dr. Chetana Roat on August 18, 2026, for Resveratrol Nanocapsule Compositions And Methods Of Treating Triple-Negative Breast Cancer..
Inventors include Mehta Drashti Anilkumar; and Dr. Chetana Roat.
The application for the patent was published on October 02, 2026, under issue no. 40/2026.
Abstract: ABSTRACT [1] Triple-negative breast cancer (TNBC) remains one of the most aggressive and challenging malignancies to treat due to the absence of estrogen, progesterone, and human epidermal growth factor receptor 2 (HER2) expressions, which precludes the use of conventional receptor-targeted therapies. Resveratrol, a naturally occurring polyphenol, has demonstrated potent chemopreventive and therapeutic efficacy against various cancer pathways; however, its clinical translation is severely restricted by poor aqueous solubility, rapid systemic metabolism, and low bioavailability. [2] To overcome these pharmacokinetic barriers, this disclosure introduces novel resveratrol-loaded nanocapsule compositions engineered for site-specific delivery and enhanced therapeutic index against TNBC. The engineered nanocapsules feature a biocompatible polymeric or lipid core-shell architecture functionalized with surface ligands to actively target overexpressed surface receptors on TNBC cells. In vitro characterization indicated that the nanocapsule formulations significantly enhance the aqueous stability of resveratrol and exhibit a controlled, sustained-release kinetic profile. Cellular uptake and cytotoxicity assays revealed superior intracellular accumulation and a marked increase in apoptosis induction in TNBC cell lines (e.g., MDA-MB-231) compared to free resveratrol. [3] Furthermore, in vivo evaluations using TNBC tumor-bearing mouse models demonstrated accelerated tumor growth regression, localized accumulation via the enhanced permeability and retention (EPR) effect, and a substantial reduction in systemic toxicity. The disclosed methods of treatment utilizing these functionalized nanocapsule compositions represent a promising, highly efficient, and biocompatible nano-drug delivery platform capable of overcoming conventional physiological barriers and improving clinical outcomes for patients suffering from aggressive triple-negative breast cancer
Disclaimer: Curated by HT Syndication.
